

NEKTAR THERAPEUTICS
Form SD
May 15, 2017

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM SD

Specialized Disclosure Report

NEKTAR THERAPEUTICS

(Exact name of registrant as specified in its charter)

| | | |
|---|--------------------------------------|---|
| Delaware (State or other jurisdiction of | 0-24006 (Commission | 94-3134940 (IRS Employer |
| incorporation or organization) | File Number) | Identification No.) |

455 Mission Bay Boulevard South

San Francisco, California
(Address of principal executive offices)

Mark A. Wilson

94158
(Zip Code)

Edgar Filing: NEKTAR THERAPEUTICS - Form SD

Vice President and General Counsel

(415) 482-5300

(Name and telephone number, including area code, of the person to contact in connection with this report.)

Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in the form applies:

Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1, 2015 to December 31, 2016.

Section 1 Conflict Minerals Disclosure

Item 1.01 Conflict Minerals Disclosure and Report

This Form SD is filed by Nektar Therapeutics (the Company) pursuant to Rule 13p-1 promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period January 1, 2015 to December 31, 2016.

A copy of the Company s Conflict Minerals Report is provided as Exhibit 1.01 to this Form SD, and is publicly available on the Company s website at www.nektar.com under the heading Investors within the Financials & Filings tab.

Item 1.02 Exhibit

The Conflict Minerals Report required by Items 1.01 and 1.02 is filed as Exhibit 1.01 to this Form SD.

Section 2 Exhibits

Item 2.01 Exhibits

Exhibit 1.01 Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

NEKTAR THERAPEUTICS

Date: May 15, 2017

/s/ Mark A. Wilson
Mark A. Wilson
Vice President and General Counsel